Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | BID | P55957 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072670 | 1.00 | DRD2 (0.40) | DRD2NPC1RAB9ACFTRCNR2 | |
| SCHEMBL8997174 | 0.91 | PDE4A (0.38) | CFTRCNR2MAPTMMP13OPRK1 | |
| SCHEMBL9844763 | 0.86 | NPC1 (0.36) | DRD2NPC1RAB9AMAPTPTPN1 | |
| SCHEMBL9844748 | 0.84 | DRD2 (0.39) | DRD2CFTRMAPTMMP13P2RX7 | |
| SCHEMBL8997137 | 0.82 | BRD4 (0.36) | NPC1RAB9AMAPTP2RX7PDE4A | |
| SCHEMBL9439773 | 0.79 | BCL2L11 (0.34) | CFTRCNR2BCL2L11BCL2BID | |
| SCHEMBL9844745 | 0.77 | MAPT (0.35) | NPC1RAB9AMAPTTLR7KDM4E | |
| SCHEMBL9844781 | 0.75 | DRD2 (0.40) | DRD2CFTRMAPTOPRK1TLR7 | |
| SCHEMBL8997195 | 0.63 | ATIC (0.35) | MAPTTLR7 | |
| SCHEMBL521422 | 0.62 | TSHR (0.67) | NPC1RAB9AMAPTPTPN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | claimed |
| JP-4790703-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | claimed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| EP-0334636-B1 | Pyrrolopyrimidine derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5539113-A | ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| US-5296600-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| US-5106974-A | Antitumor and -carcinogenic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
| US-4997838-A | Antitumor agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0334636-A2 | Pyrrolopyrimidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | DRD2 179/4885NPC1 2615/4885RAB9A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.